Capital Management Associates (New York)’s iShares Biotechnology ETF IBB Stock Holding History

Capital Management Associates (New York)’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$761K	Hold	4,000	–	–	0.98%	38
2026 Q1	$675K	Hold	4,000	–	–	1.12%	34
2025 Q4	$675K	Buy	+4,000	New	+$650K	0.99%	38
2022 Q1	–	Sell	-9,600	Closed	-$1.47M	–	84
2021 Q4	$1.47M	Hold	9,600	–	–	1.43%	24
2021 Q3	$1.55M	Hold	9,600	–	–	1.53%	17
2021 Q2	$1.57M	Hold	9,600	–	–	1.51%	17
2021 Q1	$1.45M	Hold	9,600	–	–	1.49%	23
2020 Q4	$1.45M	Hold	9,600	–	–	1.59%	16
2020 Q3	$1.3M	Hold	9,600	–	–	1.71%	15
2020 Q2	$1.31M	Buy	+9,600	New	+$1.22M	1.85%	14

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Capital Management Associates (New York)'s IBB Position: Q2 2026 in Review

Capital Management Associates (New York) held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 4,000 shares worth $761K. The position accounts for 0.98% of the portfolio, ranked #38.

Capital Management Associates (New York) first reported a position in IBB in Q2 2020 and has held it in 10 quarters since. The position peaked at $1.57M in Q2 2021. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Capital Management Associates (New York) held 4,000 shares of iShares Biotechnology ETF worth $761K as of Q2 2026.
Capital Management Associates (New York) left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.98% of Capital Management Associates (New York)'s portfolio in Q2 2026, its #38 holding.
Capital Management Associates (New York) first reported a position in iShares Biotechnology ETF in Q2 2020 and has held it in 10 quarters since.
Capital Management Associates (New York)'s iShares Biotechnology ETF position peaked at $1.57M in Q2 2021.
960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Capital Management Associates (New York)'s 13F filing for Q2 2026, filed 10 Aug 2026.